Cargando…

FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial

INTRODUCTION: 0.9% saline and Ringer’s lactate are the two most common resuscitation crystalloid fluids. 0.9% saline may lead to hyperchloraemic metabolic acidosis and may be associated with impaired kidney function and death. Few large multicentre randomised trials have been conducted to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: McIntyre, Lauralyn, Taljaard, Monica, McArdle, Tracy, Fox-Robichaud, Alison, English, Shane W, Martin, Claudio, Marshall, John, Menon, Kusum, Muscedere, John, Cook, Deborah J, Weijer, Charles, Saginur, Raphael, Maybee, Alies, Iyengar, Akshai, Forster, Alan, Graham, Ian D, Hawken, Steven, McCartney, Colin, Seely, Andrew JE, Stiell, Ian G, Thavorn, Kednapa, Fergusson, Dean A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112401/
https://www.ncbi.nlm.nih.gov/pubmed/30139908
http://dx.doi.org/10.1136/bmjopen-2018-022780
_version_ 1783350846450302976
author McIntyre, Lauralyn
Taljaard, Monica
McArdle, Tracy
Fox-Robichaud, Alison
English, Shane W
Martin, Claudio
Marshall, John
Menon, Kusum
Muscedere, John
Cook, Deborah J
Weijer, Charles
Saginur, Raphael
Maybee, Alies
Iyengar, Akshai
Forster, Alan
Graham, Ian D
Hawken, Steven
McCartney, Colin
Seely, Andrew JE
Stiell, Ian G
Thavorn, Kednapa
Fergusson, Dean A
author_facet McIntyre, Lauralyn
Taljaard, Monica
McArdle, Tracy
Fox-Robichaud, Alison
English, Shane W
Martin, Claudio
Marshall, John
Menon, Kusum
Muscedere, John
Cook, Deborah J
Weijer, Charles
Saginur, Raphael
Maybee, Alies
Iyengar, Akshai
Forster, Alan
Graham, Ian D
Hawken, Steven
McCartney, Colin
Seely, Andrew JE
Stiell, Ian G
Thavorn, Kednapa
Fergusson, Dean A
author_sort McIntyre, Lauralyn
collection PubMed
description INTRODUCTION: 0.9% saline and Ringer’s lactate are the two most common resuscitation crystalloid fluids. 0.9% saline may lead to hyperchloraemic metabolic acidosis and may be associated with impaired kidney function and death. Few large multicentre randomised trials have been conducted to evaluate the effect of these two fluids on clinically important outcomes. METHODS: FLUID is a pragmatic pilot cluster randomised crossover trial in which four hospitals will be randomised to normal saline or Ringer’s lactate for 14 weeks, then crossover to the alternative fluid for the subsequent 14 weeks after 1 to 3 week transition. With waiver of informed consent, all adult and paediatric patients admitted to participating sites will be included in the FLUID trial except for neonates. Primary feasibility outcome is study fluid protocol adherence (target:≥80%). Secondary feasibility outcomes include time to research ethics board (REB) approval and readiness to trial initiation (≤3 months from REB submission and approval). Primary (composite of death or re-admission to hospital in first 90 days of index hospitalisation) and secondary clinical outcomes for the future large FLUID trial will be described. Protocol adherence will be collected by site at specified time points. All clinical data will be obtained at patient level through provincial health administrative data held at the Institute for Clinical Evaluative Sciences (ICES). Event rates for the primary and secondary outcomes will be described using frequencies and proportions with 95% CIs. Intracluster and interperiod correlation coefficients will be calculated from population-level data available at ICES. ETHICS AND DISSEMINATION: The study protocol has been approved by the Ottawa Health Science Research Ethics Board. The FLUID pilot will determine feasibility, and ICES data across all potential sites in Ontario will allow calculation of sample size parameter estimates to inform the design and implementation of the large trial. TRIAL REGISTRATION NUMBER: NCT02721485; Pre-results.
format Online
Article
Text
id pubmed-6112401
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-61124012018-08-30 FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial McIntyre, Lauralyn Taljaard, Monica McArdle, Tracy Fox-Robichaud, Alison English, Shane W Martin, Claudio Marshall, John Menon, Kusum Muscedere, John Cook, Deborah J Weijer, Charles Saginur, Raphael Maybee, Alies Iyengar, Akshai Forster, Alan Graham, Ian D Hawken, Steven McCartney, Colin Seely, Andrew JE Stiell, Ian G Thavorn, Kednapa Fergusson, Dean A BMJ Open Epidemiology INTRODUCTION: 0.9% saline and Ringer’s lactate are the two most common resuscitation crystalloid fluids. 0.9% saline may lead to hyperchloraemic metabolic acidosis and may be associated with impaired kidney function and death. Few large multicentre randomised trials have been conducted to evaluate the effect of these two fluids on clinically important outcomes. METHODS: FLUID is a pragmatic pilot cluster randomised crossover trial in which four hospitals will be randomised to normal saline or Ringer’s lactate for 14 weeks, then crossover to the alternative fluid for the subsequent 14 weeks after 1 to 3 week transition. With waiver of informed consent, all adult and paediatric patients admitted to participating sites will be included in the FLUID trial except for neonates. Primary feasibility outcome is study fluid protocol adherence (target:≥80%). Secondary feasibility outcomes include time to research ethics board (REB) approval and readiness to trial initiation (≤3 months from REB submission and approval). Primary (composite of death or re-admission to hospital in first 90 days of index hospitalisation) and secondary clinical outcomes for the future large FLUID trial will be described. Protocol adherence will be collected by site at specified time points. All clinical data will be obtained at patient level through provincial health administrative data held at the Institute for Clinical Evaluative Sciences (ICES). Event rates for the primary and secondary outcomes will be described using frequencies and proportions with 95% CIs. Intracluster and interperiod correlation coefficients will be calculated from population-level data available at ICES. ETHICS AND DISSEMINATION: The study protocol has been approved by the Ottawa Health Science Research Ethics Board. The FLUID pilot will determine feasibility, and ICES data across all potential sites in Ontario will allow calculation of sample size parameter estimates to inform the design and implementation of the large trial. TRIAL REGISTRATION NUMBER: NCT02721485; Pre-results. BMJ Publishing Group 2018-08-23 /pmc/articles/PMC6112401/ /pubmed/30139908 http://dx.doi.org/10.1136/bmjopen-2018-022780 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Epidemiology
McIntyre, Lauralyn
Taljaard, Monica
McArdle, Tracy
Fox-Robichaud, Alison
English, Shane W
Martin, Claudio
Marshall, John
Menon, Kusum
Muscedere, John
Cook, Deborah J
Weijer, Charles
Saginur, Raphael
Maybee, Alies
Iyengar, Akshai
Forster, Alan
Graham, Ian D
Hawken, Steven
McCartney, Colin
Seely, Andrew JE
Stiell, Ian G
Thavorn, Kednapa
Fergusson, Dean A
FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial
title FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial
title_full FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial
title_fullStr FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial
title_full_unstemmed FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial
title_short FLUID trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial
title_sort fluid trial: a protocol for a hospital-wide open-label cluster crossover pragmatic comparative effectiveness randomised pilot trial
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112401/
https://www.ncbi.nlm.nih.gov/pubmed/30139908
http://dx.doi.org/10.1136/bmjopen-2018-022780
work_keys_str_mv AT mcintyrelauralyn fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT taljaardmonica fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT mcardletracy fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT foxrobichaudalison fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT englishshanew fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT martinclaudio fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT marshalljohn fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT menonkusum fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT muscederejohn fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT cookdeborahj fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT weijercharles fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT saginurraphael fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT maybeealies fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT iyengarakshai fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT forsteralan fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT grahamiand fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT hawkensteven fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT mccartneycolin fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT seelyandrewje fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT stielliang fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT thavornkednapa fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial
AT fergussondeana fluidtrialaprotocolforahospitalwideopenlabelclustercrossoverpragmaticcomparativeeffectivenessrandomisedpilottrial